<DOC>
	<DOCNO>NCT00852566</DOCNO>
	<brief_summary>A randomized multi-center study compare effect dasatinib imatinib malignant stem cell newly diagnose chronic phase chronic myeloid leukemia ( CML ) patient . The research hypothesis treatment dasatinib 100 mg daily ( QD ) result great rapid depletion Philadelphia ( Ph ) -positive stem cell pool within 6 month therapy imatinib 400 mg QD newly diagnose CML patient . The study duration 18 month approximately 40 patient recruit study .</brief_summary>
	<brief_title>Randomized Study Comparing Effect Dasatinib Imatinib Malignant Stem Cells Chronic Myeloid Leukemia</brief_title>
	<detailed_description>An Open-Label , Randomized , Multicenter Phase II Trial Comparing depletion malignant stem cell Dasatinib vs. Imatinib Patients Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Estimated Number Study Centers Countries/Regions : Appr . 12 site 5 Nordic country . Stem cell analysis perform 4 Nordic center ( Helsinki , Lund , Oslo Stockholm ) . Study Phase : II Research Hypothesis : Treatment dasatinib 100 mg daily ( QD ) result great rapid depletion Philadelphia ( Ph ) -positive stem cell pool within 6 month therapy imatinib 400 mg QD newly diagnose chronic phase ( CP ) chronic myeloid leukemia ( CML ) patient . Primary Objective : To compare number Ph-positive cell stem cell compartment newly diagnose CP CML patient treat dasatinib 100 mg QD vs. imatinib 400 mg QD . Study Design : open-label randomized Phase II trial newly diagnose CML patient CP . Patients randomize receive dasatinib start dose 100 mg QD imatinib start dose 400 mg QD . Duration Study : The study open enrollment plan number 40 patient randomize . All patient treat and/or follow 18 month . Based amendment 1 ( Oct 2011 ) , follow-up patient continue additional 4 year 31.12.2015 . Number Patients per Group : Approximately 40 patient randomize , 20 patient dasatinib 20 imatinib . Additional patient recruit case insufficient amount representative sample obtain first 40 patient . Study Population : Patients 18 year old newly diagnose CP CML , previously treat systemic treatment CML Study Assessments Endpoints : All stem cell assay base preselection CD34+ cell large volume bone marrow ( BM ) aspirate use paramagnetic bead . The CD34+ fraction subdivide base expression CD38 marker ( positive vs. negative ) use sort flow cytometer . The primary endpoint comparison proportion Ph-positive cell stem cell compartment ( CD34+CD38neg CD34+CD38+ ) 6 month study arm . Secondary endpoint comparison treatment arm : ( 1 ) number Ph-positive cell stem cell compartment 1 3 month , ( 2 ) BCR-ABL RQ-PCR blood 1 , 3 , 6 , 12 18 month , ( 3 ) rate CCyR within 3 , 6 , 12 18 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Patients able provide write informed consent Patients must CML CP define presence follow criterion : &lt; 15 % blast peripheral blood ( PB ) BM . &lt; 30 % blast plus promyelocytes PB BM . &lt; 20 % basophil PB . ≥ 100 x 109/L platelet . No evidence extramedullary leukemia apart hepatosplenomegaly Ph+ variant must demonstrate BM cytogenetics , FISH PCR . Previously untreated CML CP , exception hydroxyurea anagrelide Patients must enrol study within 90 day date first diagnose CML ECOG Performance Status ( PS ) Score 0 1 ( see Appendix 2 ) Adequate hepatic function define : total bilirubin ≤ 2.0 time institutional upper limit normal ( ULN ) absence Gilbert type unconjugated hyperbilirubinemia ; alanine aminotransferase ( ALAT≤ 2.5 time institutional ULN . Adequate renal function define serum creatinine ≤ 2 time institutional ULN . Men woman , age 18 year old . Adequate BM aspiration sample start study treatment ( i.e sample sufficient stem cell analysis ) Potentially fertile woman must use adequate method contraception avoid pregnancy throughout study . Potentially fertile woman must negative serum urine pregnancy test Fertile woman unwilling unable use acceptable method avoid pregnancy entire study Women pregnant breastfeeding . Men fertile sexual partner use acceptable contraception method entire study A serious uncontrolled medical disorder active infection would impair ability subject receive protocol therapy . Known pleural effusion baseline . Uncontrolled significant cardiovascular disease History significant bleeding disorder unrelated CML , include : Prior chemotherapy peripheral stem cell mobilization . Inadequate BM aspiration sample due marrow fibrosis reason Prior concurrent malignancy Severe psychiatric illness , imprisonment mental impairment inflict ability give inform consent Abuse alcohol , prescribe illicit drug Evidence digestive dysfunction would prevent administration study therapy mouth . Prohibited Treatments and/or Therapies Any prior treatment interferon Any prior treatment dasatinib Any prior treatment imatinib Any prior systemic treatment , antiCML activity [ except anagrelide , hydroxyurea ( HU ) ] . Patients currently take drug generally accept risk cause Torsades de Pointes describe Appendix 3 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>stem cell</keyword>
	<keyword>Philadelphia chromosome</keyword>
	<keyword>dasatinib</keyword>
</DOC>